Introduction
Maternal iron deficiency anemia remains a critical global health challenge affecting nearly 40% of pregnant women worldwide. This secondary analysis investigates the crucial relationship between hematologic response to iron therapy and perinatal outcomes in pregnancies complicated by moderate iron deficiency anemia. The findings reveal that inadequate hemoglobin improvement at mid-pregnancy significantly elevates the risk of devastating outcomes like stillbirth and early preterm delivery.
